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Background: Among HIV-infected women, perinatal depression
compromises clinical, maternal, and child health outcomes. Anti-
retroviral therapy (ART) is associated with lower depression
symptom severity but the uniformity of effect through pregnancy
and postpartum periods is unknown.
Methods: We analyzed prospective data from 447 HIV-infected
women (18–49 years) initiating ART in rural Uganda (2005–2012).
Participants completed blood work and comprehensive question-
naires quarterly. Pregnancy status was assessed by self-report. Anal-
ysis time periods were deﬁned as currently pregnant, postpartum (0–
12 months post-pregnancy outcome), or non–pregnancy-related.
Depression symptom severity was measured using a modiﬁed
Hopkins Symptom Checklist 15, with scores ranging from 1 to 4.
Probable depression was deﬁned as .1.75. Linear regression with
generalized estimating equations was used to compare mean depres-
sion scores over the 3 periods.
Results: At enrollment, median age was 32 years (interquartile
range: 27–37), median CD4 count was 160 cells per cubic millimeter
(interquartile range: 95–245), and mean depression score was 1.75
(s = 0.58) (39% with probable depression). Over 4.1 median years of
follow-up, 104 women experienced 151 pregnancies. Mean depres-
sion scores did not differ across the time periods (P = 0.75). Multi-
variable models yielded similar ﬁndings. Increasing time on ART,
viral suppression, better physical health, and “never married” were
independently associated with lower mean depression scores. Find-
ings were consistent when assessing probable depression.
Conclusions: Although the lack of association between depression
and perinatal periods is reassuring, high depression prevalence at
treatment initiation and continued incidence across pregnancy and
non–pregnancy-related periods of follow-up highlight the critical
need for mental health services for HIV-infected women to optimize
both maternal and perinatal health.
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INTRODUCTION
Depression is a serious global public health issue,1,2
particularly among women of reproductive age.3 People liv-
ing with HIV have higher rates of depression compared with
those observed in the general population in western4,5 and
sub-Saharan African countries.6 Among HIV-infected indi-
viduals, depression has deleterious effects on psychological
well-being and quality of life6 and undermines HIV treatment
through associations with poor adherence to antiretroviral
therapy (ART),7–10 HIV disease progression,11 CD4 cell count
decline, virologic failure,12,13 and increased mortality.14
Among HIV-infected women in Uganda and other sub-
Saharan African countries, 15%–50% screen positive for prob-
able depression.6,15–18 A high incidence of pregnancy19,20 and
burden of perinatal depression among HIV-infected women21–23
further compromises HIV-related clinical, immunologic,
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and virologic outcomes,24 as well as overall maternal
health. Maternal depression also impacts child health out-
comes, including risks of perinatal HIV transmission, poor
physical health,25 impaired cognitive, behavioral, and psy-
chomotor development,26 and delayed socio-emotional
development.27
Access to ART has expanded dramatically in HIV
endemic, resource-limited settings,28 yielding clinical29–32 and
population-level beneﬁts.33–35 Recent data from sub-Saharan
Africa suggest that receipt of ART is also associated with lower
depression symptom severity,36–38 through physiological, psy-
chological, and stigma reduction pathways.39,40 However, the
extent to which ART affects depression across perinatal peri-
ods is not known.
The primary objective of this prospective study was to
measure and compare depression symptom severity during
non–pregnancy-related, pregnant, and postpartum periods
among HIV-infected women initiating ART in rural Uganda.
Understanding the relationship between depression and peri-
natal periods among women on ART may inform reproduc-
tive and mental health programming for HIV-infected
women considering pregnancy to optimize maternal and
perinatal health.
METHODS
Study Setting
Uganda is an important setting in which to investigate
depression over perinatal periods given a total fertility rate of
6.2 births per woman41 and HIV prevalence of 7.2%,20,42 high-
er among women (8.2%) than among men (6.1%). In addition,
70% of treatment-eligible Ugandans access ART.20,28 ART
coverage among women with pregnancy is expected to
increase with Uganda’s adoption of “Option B+” to prevent
perinatal HIV transmission.43,44
Mbarara District is a primarily rural setting located
approximately 265 km southwest of Kampala. Adult HIV
prevalence in the district is estimated at 10%45 and is higher
among women compared with men. The Mbarara University
HIV clinic is located within the Mbarara Regional Referral
Hospital and offers comprehensive HIV care services, includ-
ing ART, at no cost to patients.46
Study Participants
Study participants were enrolled in the Uganda
AIDS Rural Treatment Outcomes (UARTO) cohort study,
initiated in July 2005 with the primary objective of
determining predictors of virologic failure and antiretro-
viral resistance. Participants were recruited from HIV-
infected, treatment-naive adults initiating ART at the
Mbarara University HIV clinic. Patients who were at least
18 years old and living within 60 km of the clinic were
eligible to enroll. At the time of this analysis, 447 women
were enrolled in UARTO. Loss-to-follow-up (participants
for whom we were unable to conﬁrm vital status after
$180 days without cohort follow-up) was 2% at 1 year
and 5% at 2 years after enrollment.
Data Collection
Participants were seen at baseline (ie, at ART initiation)
and quarterly for bloodwork and to complete standardized
interviewer-administered questionnaires detailing sociodemo-
graphics, mental and physical health, sexual risk behaviour,
and partner dynamics. Incident pregnancies were assessed by
self-report. Interviews were administered in the dominant
local language (Runyankole). This analysis includes data
from female participants (18–49 years) enrolled from June
2005 followed through December 2012.
Measures
Primary Outcome: Depression
Depression symptom severity was measured using
a modiﬁed version of the Hopkins Symptom Checklist
(HSCL)-15 for depression.47 Based on previous studies using
HSCL in Uganda, we included a 16th item, “Feeling like I
don’t care about my health.”48 Each symptom was scored on
a 4-item Likert scale ranging from 1 (not at all) to 4
(extremely) and the total depression severity score was cal-
culated as the mean of the 16 items, with higher scores indi-
cating greater depression symptom severity. We also assessed
a dichotomous measure of “probable depression” deﬁned as
an HSCL score .1.75, a commonly used threshold for a pos-
itive screen of depression.47–50
The depression subscale of HSCL has been used to
assess depression in general population samples and among
people living with HIV in sub-Saharan African coun-
tries.47–49,51–54 The HSCL has been further shown to have
good reliability55 and construct validity56 among people
living with HIV in Uganda speciﬁcally. Although the
HSCL was not designed to speciﬁcally screen for perinatal
depression, it and other generic depression scales are com-
monly used to measure depression among antenatal
women.54,57–59 The most reliable, valid, and frequently used
measure of perinatal depression in sub-Saharan Africa is
the Edinburgh Postnatal Depression Scale54; however, the
reliability and validity of the Edinburgh Postnatal Depres-
sion Scale outside of perinatal periods is unknown.
Primary Predictor Variable: Pregnancy Status
The primary predictor variable is a 3-level variable
indicating pregnancy status, which we classiﬁed as being
pregnant, up to 1 year postpartum or neither pregnant nor
post-partum (“non–pregnancy-related”). Women who re-
ported sterilization (tubal ligation or hysterectomy) at baseline
were excluded from the analysis. If the procedure was re-
ported during follow-up, women were censored upon reported
date of the procedure.
Periods of pregnancy were deﬁned based on self-report at
baseline and over the follow-up period and included both ﬁrst
and subsequent pregnancies. Pregnancy start was deﬁned as the
visit date when pregnancy was ﬁrst reported and pregnancy end
was the subsequent date at which women reported no longer
being pregnant. For the few women (n = 8) who reported a live
birth outcome and had a computed period of pregnancy of,7 or
.11 months, live birth date was used to back-calculate a start
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date to account for an estimated 9-month gestation. The post-
partum period was deﬁned as the period from the end of preg-
nancy until 12 months after any pregnancy outcome.60,61 All
other follow-up times were assessed as non–pregnancy-related.
At study enrollment, women reported whether they were
or had been pregnant in the previous 12 months but did not
report dates of pre-enrollment pregnancy or postpartum status.
Thus, no women were classiﬁed as postpartum at study entry.
Covariates
We examined the association between depression and
pregnancy status, adjusting for baseline and time-updated
covariates considered potential confounders. Baseline varia-
bles included sociodemographic characteristics (including
age, education, employment, household income, and marital
status), reproductive history (including parity), and clinical
history (including time since HIV diagnosis, AIDS deﬁning
illnesses, CD4 cell count at enrollment, and body mass
index). Time-updated variables were measured quarterly
and included age, time on HIV treatment, CD4 cell count,
HIV viral load ,400 copies per milliliter (ie, viral suppres-
sion), the Medical Outcomes Study HIV Health Survey Phys-
ical Health Summary score (scored on a 0–100 scale, where
a higher score indicates better health),62,63 and sexual activity
in the previous 3 months.
Data Analysis
Descriptive statistics were used to characterize base-
line distributions of study variables. Baseline differences
between women with and without incident pregnancy were
compared using Wilcoxon rank sum test for continuous
variables and Pearson x2 test for categorical variables.
Although our regression models are based on time-varying
pregnancy-related status, comparison of ﬁxed categories of
pregnancy are provided to inform understanding of differ-
ences between women who exclusively contributed to non-
pregnant periods and those who contributed to all 3 periods
of follow-up.
We calculated the mean (SD) HSCL score at baseline
and then compared mean HSCL scores across pregnant,
postpartum, and non–pregnancy-related periods using analy-
sis of variance. We plotted mean HSCL scores (with residual
standard error bars) across the 3 periods by time on ART. We
ﬁt a multivariable linear regression model to the data, using
generalized estimating equations to estimate model parame-
ters. We used an autoregressive working correlation structure.
Pregnancy and the postpartum period were investigated as
independent predictors of depression symptom severity. After
testing normality assumptions and collinearity, variables with
a signiﬁcant association with depression in bivariate analyses
(at P , 0.20) were considered for the full model to obtain the
relative contribution of each covariate. Model selection was
achieved by minimizing the Akaike Information Criterion
while maintaining P-values for covariates below 0.20.64 All
statistical tests were 2-sided and were considered statistically
signiﬁcant at a = 0.05. Using a binary variable for “probable
depression,” we also ﬁt a multivariable GEE logistic regression
model. The same model selection procedures and covariates
were used. Data were analyzed with SAS version 9.3 (SAS
Institute Inc., Cary, NC).65
Ethical Statement
All participants provided voluntary, written informed
consent at study enrollment. Ethical approval for all study
procedures was obtained from the Institutional Review
Committee, Mbarara University of Science and Technology;
the Partners Human Research Committee, Massachusetts
General Hospital; the Committee on Human Research,
University of California at San Francisco; and the Research
Ethics Board of Simon Fraser University. Consistent with
national guidelines, we received clearance for the study from
the Uganda National Council for Science and Technology and
from the Research Secretariat in the Ofﬁce of the President.
RESULTS
Baseline Characteristics
Overall, 447 women aged 18–49 years with baseline
data were eligible for this study. The analysis was restricted
to 407 nonsterilized women with at least 1 follow-up visit.
Participants contributed 1564.6 person-years (PYs) of follow-
up with a median follow-up time of 4.1 years [interquartile
range (IQR): 0.9–5.6 years].
Median age was 32 years (IQR: 27–37 years), 25% had
more than a primary school education, 69% were employed, and
median monthly household income was 35,000 (IQR: 10,000–
100,000) Ugandan Shillings (;$14 USD). Forty-one percent of
women were currently married or living as married. Of 184
married women, 63% reported an HIV-positive spouse, of whom
53% were on ART. Median number of previous live births was 3
(IQR: 1–5) and 52% were sexually active. Median time between
HIV diagnosis and ART initiation was 15 months (IQR: 4–40
months), 44% reported ever having an AIDS-deﬁning illness,
and median body mass index was 21.9 kg/m2 (IQR: 20.1–24.8
kg/m2). Median CD4 cell count at enrollment was 160 cells per
cubic millimeter (IQR: 95–245 cells/mm3) and median Medical
Outcomes Study HIV Health Survey Physical Health Summary
score was 53 (IQR: 45–59). The mean depression symptom
severity score at baseline was 1.75 (SD = 0.58) with 39% of
women screening positive for probable depression (Table 1).
Depression Symptom Severity by
Pregnancy Status
Among 407 women with at least 1 follow-up visit, 104
women reported 151 pregnancies over the follow-up period. In
unadjusted analyses, the mean depression symptom severity
score did not differ across periods [1.28 (s = 0.37) during non–
pregnancy-related periods, 1.29 (s = 0.38) during pregnant
periods, and 1.34 (s = 0.49) during postpartum periods; P =
0.749]. Factors associated with lower depression symptom
severity included increasing time on ART, viral suppression,
better physical health, and having never been married.
After adjusting for covariates, there remained no
signiﬁcant difference in depression symptom severity scores
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by pregnancy status. However, depression scores during
the postpartum were slightly elevated compared with non–
pregnancy-related periods [b = 0.05; 95% conﬁdence interval
(CI): 20.01 to 0.10; P = 0.098]. In the adjusted model
(Table 2), increased cumulative duration of ART receipt
[mean score decreased by 0.14 after 6 months (b = 20.14;
95% CI: 20.17 to 20.11) and by 0.22 after 24 months of
ART receipt (b = 20.22; 95% CI: 20.26 to 20.19], viral
suppression (b = 20.20; 95% CI: 20.24 to 20.16), better
physical health (b = 20.16; 95% CI: 20.18 to 20.13), and
being never married (b = 20.10; 95% CI: 20.16 to 20.04)
compared with currently married were independently associ-
ated with lower depression symptom severity. The decline in
mean depression symptom severity score across the 3 periods
by increasing time on ART is shown in Figure 1.
Probable Depression by Pregnancy Status
The proportion of study visits where women screened
positive for probable depression did not differ across periods.
The criteria for probable depression was met during 9.5% of
study visits overall, including 9.3% of non–pregnancy-related
visits, 10.3% of pregnant visits, and 12.1% of postpartum
visits (P = 0.37). Consistent with linear models, in adjusted
logistic models, increasing time on ART [adjusted odds ratio
(aOR) = 0.48; 95% CI: 0.37 to 0.61 after 6 months and aOR =
0.22; 95% CI: 0.16 to 0.30 after 24 months], viral suppression
(aOR: 0.45; 95% CI: 0.35 to 0.56), better physical
health (aOR: 0.30; 95% CI: 0.24 to 0.39), and being never
married (aOR: 0.51; 95% CI: 0.30 to 0.88 compared with
being married) were independently associated with lower
odds of probable depression (Table 2). The unadjusted odds
of probable depression are included in Table S1 (see Supple-
mental Digital Content, http://links.lww.com/QAI/A586).
DISCUSSION
Among HIV-infected women on ART, we found no
difference in depression symptom severity between pregnant
and postpartum periods compared with non–pregnancy-related
TABLE 1. Baseline Characteristics of Participants (18–49 Years) by Pregnancy Status After ART Initiation*
Characteristic
Overall (n = 447),
n (%) or Median (IQR)
Pregnancy After
ART Initiation
(n = 104),
n (%) or Median (IQR)
No Pregnancy After
ART Initiation
(n = 303),
n (%) or Median (IQR) P
Median follow-up (yrs) 4.1 (0.9–5.6) 5.1 (3.9–5.8) 3.9 (0.9–5.8) ,0.001
Sociodemographic characteristics
Median age (yrs) 32 (27–37) 29 (25–33) 34 (28–38) ,0.001
Employed 309 (69.1%) 58 (55.8%) 224 (73.9%) ,0.001
Education: post-primary school 113 (25.3%) 21 (20.2%) 83 (27.4%) 0.154
Median monthly household income (1000 UGX)† 35 (10–100) 30 (10–54) 36 (10–100) 0.391
Marital status
Married‡ 184 (41.3%) 60 (57.7%) 110 (36.5%) ,0.001
Never married 37 (8.3%) 9 (8.7%) 24 (8.0%)
Widowed 104 (23.4%) 12 (11.5%) 84 (27.9%)
Divorced 120 (27.0%) 23 (22.1%) 83 (27.6%)
Median no. live births 3 (1–5) 3 (1–4) 3 (1–5) 0.622
Clinical status characteristics
Median time between HIV diagnosis and ART
initiation (mo)
15.1 (4.1–40.4) 12.8 (5.1–29.9) 16.2 (3.9–43.8) 0.171
Ever had AIDS deﬁning illness 197 (44.4%) 50 (48.5%) 128 (42.5%) 0.302
BMI (kg/m2) 0.408
,18.5 48 (11.3%) 9 (9.1%) 32 (11.1%)
18.5 , 25 282 (66.4%) 73 (73.7%) 191 (66.1%)
25 or more 95 (22.4%) 17 (17.2%) 66 (22.8%)
“Probable depression”§ 173 (38.9%) 44 (42.7%) 111 (36.8%) 0.293
Median CD4 (cells/mm3) 160 (95–245) 163 (90–245) 162 (99–241) 0.948
MOS-HIV physical health summary score 55.0 (45.3–59.4) 56.2 (48.2–59.1) 54.1 (44.9–59.2) 0.197
Sexual behaviour characteristics
Had sex in the past 3 mo 231 (51.7%) 70 (67.3%) 143 (47.2%) ,0.001
Spouse HIV-positivek 116 (63%) 35 (58.3%) 70 (63.6%) 0.270
*Four hundred forty-seven women had enrollment information and are counted in the “Overall” column. 407 women had one or more follow-up visits and were not sterilized at
baseline (ie, 40 women are excluded from the following 2 columns assessing pregnancy post-ART initiation).
†UGX is the currency symbol for Ugandan Shillings. 35,000 UGX ; $13.90 USD (conversion rate: 1 USD = 2518.89 UGX).
‡Married or living as married, as per self-report.
§Depression was screened using the Hopkins Symptom Check List modiﬁed for use among people living with HIV, with a cut-off of .1.75 indicating “probable depression.”
kRestricted to n = 184 who reported being currently married (60 among those with pregnancy, 110 among those without pregnancy).
BMI, body mass index; MOS-HIV, Medical Outcomes Study HIV Health Survey.
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periods. Increasing time on ART and associated improvements
in viral suppression and physical health were independently
associated with declines in depression symptom severity.
We observed a high prevalence of probable depression
at ART initiation (39% of women). This prevalence was
higher than rates observed in the general Uganda population
(9%–24%)52,66 or among HIV-infected individuals in
Uganda18,67 and other sub-Saharan African settings.6,54,68
Although some degree of variability in depression estimates
may be because of heterogeneity in screening measures and
cultural-speciﬁc expressions of depression, the high rate of
probable depression observed here is cause for concern.
Over the follow-up period, we did not observe a signif-
icant difference between depression and pregnancy status,
although depression symptom severity was elevated during
postpartum visits (not statistically signiﬁcant). Findings from
other sub-Saharan African countries suggest that among
untreated HIV-infected women24 and women in general,69,70
depression rates increase during perinatal follow-up. In our
study, the high overall prevalence of depression may mask
increases associated with perinatal periods.
The prevalence of probable depression decreased with
increasing time on ART. After 6 months of treatment, odds of
depression were half those observed at baseline and after 2
years of treatment, odds of probable depression were 78%
lower compared with baseline. These results are consistent
with work showing substantial mental health beneﬁts of HIV
treatment and care, particularly within the ﬁrst year of ART
initiation.36,38 Although depression symptom severity drops
with increasing time on ART irrespective of pregnancy status,
criteria for probable depression was still met at 9.3%–12.1%
of visits across the 3 follow-up periods. Clearly, HIV treat-
ment alone does not treat mental illness among women living
with HIV and does not compensate for a lack of comprehen-
sive mental health care.
We found that improvements in physical health were
associated with signiﬁcant decreases in depression symptom
severity. This is not surprising and consistent with known
improvements in physical function that accompany HIV
treatment and care and the relationship between physical
and mental health outcomes. Moreover, recent related ﬁnd-
ings from this cohort reveal a secular trend of declining
depression symptom severity scores among participants at
study enrollment. This trend was largely explained by higher
physical health status among participants presenting for
ART initiation over time.71 In addition to the known clin-
ical29–32 and population-health33–35,72 beneﬁts of HIV treat-
ment and care, these ﬁndings suggest that earlier initiation
of ART, among HIV-infected patients in better physical and
TABLE 2. Depression Symptom Severity and Odds of Probable Depression by Pregnancy Status
Variable
Linear Regression Logistic Regression
Change in HSCL Score (b)
(95% CI) Type III P
Adjusted Odds Ratio
(95% CI) Type III P
Pregnancy status
Pregnant vs. non-pregnant 20.01 (20.05 to 0.04) 0.124 0.91 (0.58 to 1.43) 0.662
Postpartum vs. non-pregnant 0.05 (20.01 to 0.10) 1.15 (0.71 to 1.87)
Viral suppression
Yes vs. no 20.20 (20.24 to 20.16) ,0.001 0.45 (0.35 to 0.56) ,0.001
Time on ART
6–24 mo vs. 0–6 mo 20.14 (20.17 to 20.11) ,0.001 0.48 (0.37 to 0.61) ,0.001
24 or more mo vs. 0–6 mo 20.22 (20.26 to 20.19) 0.22 (0.16 to 0.30)
MOS—Physical Health summary score 20.16 (20.18 to 20.13) ,0.001 0.30 (0.24 to 0.39) ,0.001
Marital status
Never vs. married 20.10 (20.16 to 20.04) 0.003 0.51 (0.30 to 0.88) 0.003
Divorced vs. married 0.00 (20.04 to 0.05) 0.99 (0.67 to 1.45)
Widowed vs. married 0.05 (0.00 to 0.10) 1.24 (0.81 to 1.89)
Depression measured using modiﬁed HSCL-15.
After testing normality assumptions and collinearity, variables with a signiﬁcant association with depression in bivariate analyses (at P , 0.20) were considered for the full model
to obtain the relative contribution of each covariate. Model selection was achieved by minimizing the Akaike information criterion (AIC) while maintaining P-values for covariates
below 0.20.
The type III P-value considers the signiﬁcance of a variable as a whole rather than each of the categories compared with the reference category.
FIGURE 1. Mean depression symptom severity score over
time on ART by pregnancy status (note: error bars are based
on the residual standard error).
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clinical health, may have a positive impact on mental
health outcomes.
Our ﬁnding of an independent lower depression risk
among “never married” compared with “currently married”
women seems to contrast with literature suggesting a protec-
tive mental health effect of marriage. However, in general,
health beneﬁts of marital status are highly gendered, with
more protective beneﬁts for men than women.73 Such differ-
ences relate, in part, to gender and unequal power dynamics
within relationships, which are often exacerbated in the con-
text of childbearing. With respect to risk factors for postpar-
tum depression in particular, evidence suggests that the
availability of social support in general (within and/or exter-
nal to the marital relationship) is more strongly protective
against postpartum depression than marital status alone.74
Moreover, a recent Ugandan study similarly found that
co-habitation with the male partner and marital discord was
associated with higher depression scores among postpartum
women.69 A related line of research indicates that women
with greater relationship power have lower rates of depres-
sion.75 This suggests that our ﬁndings of a higher depression
risk among “currently married” compared with “never mar-
ried” women may reﬂect unmeasured discord within those
marital relationships.
The pathways through which HIV treatment may lead
to declines in depression symptom severity have been
summarized36 and include (1) improved physical health lead-
ing to better social and economic conditions; (2) facilitation
of regular access to general clinic services, counseling, and
support (including mental health services, when available)
that enable development of positive coping and resiliency;
(3) reduced neurotoxic effects of HIV; and (4) lower internal-
ized HIV-related stigma.56 Recent work has also elucidated
potential biological pathways through which HIV treatment-
mediated changes may reduce depression.39 In our observa-
tional study, reductions in depression over time on ART may
also reﬂect a retention bias if women with depression were
more likely to be lost-to-follow-up compared with women
without depression. However, such biases are unlikely to
fully explain our ﬁndings given the overall low loss-to-
follow-up rate among women enrolled in UARTO (3% and
7% at years 1 and 5, respectively) with no differences in loss-
to-follow-up between women with and without pregnancy
(7% vs. 8% at time of last observation).
Among pregnant HIV-infected women in settings with
a high cultural value on childbearing, these ﬁndings suggest
that receipt of ART and the resultant opportunity to have an
HIV-uninfected child may overwhelm other biological or
psychosocial drivers of depression. The observation of no
signiﬁcant increase in postpartum depression among women
receiving ART supports the need for research to understand
the experience of depression in the context of changing
reproductive and maternal health for HIV-infected women in
high fertility settings such as Uganda.76,77
Implications
Depression has serious consequences for HIV outcomes
and quality of life and can impact maternal and child health
and development.6,16,37 The observed high prevalence of
depression among HIV-infected women highlights the need
for clinical management of depression during and external to
perinatal periods. Currently, however, although effective
treatments are available for perinatal depression,78,79 depres-
sion is unlikely to be formally diagnosed or treated in settings
like Uganda, where mental health services are generally lim-
ited.80 In this setting, the Mbarara Regional Referral Hospital
has a full-service mental health clinic, where counseling and
medical treatment services for depression are available. A
persistent challenge, however, is that depression (during or
outside of pregnancy) often goes undetected in HIV treatment
clinics because of a lack of routine screening and referral
processes, time constraints within clinical visits, and the
underprioritization of mental health concerns relative to the
physical ailments of HIV.6 Given the high rates of depression
symptom severity among HIV-infected women initiating
ART observed here, the development, testing, and implemen-
tation of a short screening instrument and referral process
must be prioritized within HIV treatment clinics to connect
women with existing treatment and counseling services at the
onsite mental health clinic.
Additional opportunities exist to connect women with
mental health services available at smaller, community-based
health care centers throughout Mbarara District. Short and
ultra-short screening instruments are readily available for
depression screening during the perinatal period,54,81,82 but it
is unclear whether screening is ultimately associated with
improved health or mental health outcomes.83 One study from
Uganda showed that routine clinical screening for depression
among HIV-infected patients by primary care workers or
community health workers signiﬁcantly improved case detec-
tion and the proportion of patients receiving antidepressants.84
Task shifting of mental health programming to counselors
and integration within HIV services have also been shown
to be important for addressing the high burden of depression
among people living with HIV.10 To achieve better uptake
of such services, however, additional efforts are required to
increase care-seeking for depression among HIV-infected
women.6 Furthermore, any proposed screening and treat-
ment pathways must be thoroughly tested before being
widely implemented.
Limitations
This study has several limitations. First, given quarterly
follow-up and self-report of pregnancy and pregnancy out-
comes, dates used to compute periods of pregnancy vs.
postpartum vs. non–pregnancy-related are estimates and sub-
ject to misclassiﬁcation bias. Such misclassiﬁcation may have
yielded conservative estimates of risk of postpartum depres-
sion because such risks may be higher after preterm vs. term
births.74 Second, at study enrollment, women reported prev-
alent pregnancy and whether they had been pregnant in the
previous 12 months but did not report dates of pre-enrollment
pregnancy or postpartum status. Thus, no women were clas-
siﬁed as postpartum at study entry. Given high rates of
depression at baseline, including postpartum women with
non-pregnant women may have biased our comparisons of
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baseline depression toward the null. Third, others have vali-
dated the use of the HSCL-25 to measure depression symp-
tom severity in pregnancy and have suggested a much lower
cut-off to determine probable depression (HSCL . 1.06)59
rather than using the same cut-off across periods. A lower
criteria for probable depression identiﬁed a higher percentage
of women as depressed; however, in sensitivity analyses,
there remained no association between depression and
pregnancy-related periods of follow-up (data not shown).
Fourth, HSCL is a screening tool. Assessing depression in
PLWH is complicated by the potential for overlap between
somatic symptoms of depression and HIV disease85 as well as
somatic symptoms of depression and pregnancy. Depression
may also be experienced more somatically in non-western
cultures.59,79 Given uncertain cultural and/or linguistic equiv-
alency of HSCL items, future research must be informed by
locally validated measures. Finally, our participants are
enrolled in an intensive follow-up cohort study and may not
be representative of the general population of women living
with HIV.
CONCLUSIONS
The lack of association between depression and peri-
natal periods is an important ﬁnding for HIV-infected women
considering pregnancy after ART initiation and further
support the role of HIV treatment in improving maternal
health outcomes. In an HIV-endemic setting with high
cultural value of childbearing, sustained access to ART may
improve perinatal mental health for women. However, the high
prevalence of depression at treatment initiation and continued
incidence over a sustained follow-up across pregnancy and
non–pregnancy-related periods of follow-up demands prioriti-
zation of mental health programming for HIV-infected women
to optimize maternal and perinatal health.
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